Vanda Pharmaceuticals Accounts Receivables 2011-2026 | VNDA

Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.

Examples of accounts receivable

Customers have not paid invoices for delivered products
An advance has been paid to a supplier, but goods have not yet been received
Employees have not reported on accountable amounts
The government must refund tax overpayments
Outstanding loans issued

Importance of accounts receivable in company analysis

Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment.
Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages.
Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)

Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)

If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.

Annual Accounts Receivables Vanda Pharmaceuticals

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
54.6 M	47.1 M	34.2 M	33.5 M	32.5 M	30 M	26.4 M	28.8 M	17.6 M	20.3 M	16.3 M	3.65 M	2.03 M	1.17 M	1.62 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
54.6 M	1.17 M	23.3 M

Quarterly Accounts Receivables Vanda Pharmaceuticals

2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
45 M	44.6 M	47.1 M	42.8 M	41.9 M	-	34.2 M	29.3 M	33.6 M	24.5 M	33.5 M	29.4 M	-	30.5 M	32.5 M	41.5 M	37.1 M	31.5 M	30 M	30 M	30 M	30 M	26.4 M	26.4 M	26.4 M	26.4 M	28.8 M	28.8 M	28.8 M	28.8 M	17.6 M	17.6 M	17.6 M	17.6 M	20.3 M	20.3 M	20.3 M	20.3 M	16.3 M	16.3 M	16.3 M	16.3 M	3.65 M	3.65 M	3.65 M	3.65 M	2.03 M	2.03 M	2.03 M	2.03 M	1.17 M	1.17 M	1.17 M	1.17 M	1.62 M	1.62 M	1.62 M	1.62 M

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
47.1 M	1.17 M	20.9 M

Accounts Receivables of other stocks in the Biotechnology industry

Issuer	Accounts Receivables	Price	% 24h	Market Cap	Country
Amphastar Pharmaceuticals AMPH	144 M	$ 21.65	1.12 %	$ 1.01 B	USA
I-Mab IMAB	130 M	-	-	$ 866 M	China
Aptorum Group Limited APM	62.2 K	$ 0.9	-0.18 %	$ 6.62 M	China
ACADIA Pharmaceuticals ACAD	98.7 M	$ 22.3	1.55 %	$ 3.7 B	USA
Advaxis ADXS	234 K	-	-9.65 %	$ 45.9 M	USA
AIkido Pharma AIKI	200 K	-	1.93 %	$ 17.4 M	USA
Brainstorm Cell Therapeutics BCLI	312 K	-	-2.5 %	$ 5.88 M	USA
Aptinyx APTX	257 K	-	-39.0 %	$ 4.57 M	USA
AgeX Therapeutics AGE	57 K	-	-10.17 %	$ 12.2 K	USA
Aridis Pharmaceuticals ARDS	1 M	-	17.91 %	$ 11.1 M	USA
Aquestive Therapeutics AQST	17.8 M	$ 4.1	0.49 %	$ 438 M	USA
Arcutis Biotherapeutics ARQT	146 M	$ 23.42	0.69 %	$ 2.98 B	USA
Ayala Pharmaceuticals AYLA	234 K	-	-	$ 7.46 M	Israel
Autolus Therapeutics plc AUTL	24 M	$ 1.42	-1.39 %	$ 378 M	Britain
Esperion Therapeutics ESPR	140 M	$ 1.91	-	$ 397 M	USA
BioDelivery Sciences International BDSI	56.9 M	-	-4.8 %	$ 255 M	USA
BeiGene, Ltd. BGNE	865 M	-	0.49 %	$ 251 B	Cayman-islands
bluebird bio BLUE	300 K	-	-	$ 546 M	USA
Cardiff Oncology CRDF	182 K	$ 1.72	-	$ 115 M	USA
BioXcel Therapeutics BTAI	233 K	$ 1.09	2.83 %	$ 13.3 M	USA
Cara Therapeutics CARA	2.76 M	-	-3.03 %	$ 260 M	USA
CASI Pharmaceuticals CASI	9.8 M	-	-	$ 35.4 M	USA